Haussier
Johnson & Johnson's Ottava Surgical Robot Receives FDA Approval, Stock Rises Nearly 2%
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson's Ottava surgical robot has received FDA marketing authorization, marking the company's entry into the soft-tissue robotic-assisted surgery market. This development has positively impacted the stock, which rose nearly 2% following the announcement.
Points clés
- Ottava Surgical Robot Receives FDA Approval
- Insider Sells $5.79 Million in Shares
- Institutional Investors Adjust Holdings
Sources
- Johnson & Johnson's Ottava Surgical Robot Receives FDA Marketing Authorization, Stock Rises Nearly 2%VCBeat · July 23, 2026
- Johnson & Johnson (JNJ) Executive Sells Over $5.79 Million in SharesGuruFocus · July 25, 2026
- Arrowstreet Capital Limited Partnership Sells 1,504,237 Shares of Johnson & Johnson $JNJMarketBeat · July 25, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
